Laparoscopy Can Prevent Futile Primary Cytoreductive Surgery

Share this content:
Laparoscopy Can Prevent Futile Primary Cytoreductive Surgery
Laparoscopy Can Prevent Futile Primary Cytoreductive Surgery

THURSDAY, Jan. 5, 2017 (HealthDay News) -- Diagnostic laparoscopy reduces the number of futile laparotomies in women with suspected advanced-stage ovarian cancer, according to a study published online Dec. 28 in the Journal of Clinical Oncology.

Marianne J. Rutten, M.D., Ph.D., from the Academic Medical Center in Amsterdam, and colleagues conducted a randomized controlled trial that involved eight gynecologic cancer centers. Patients with suspected advanced-stage ovarian cancer who qualified for primary cytoreductive surgery (PCS) were randomly assigned to either diagnostic laparoscopy (102 patients) or primary surgery (99 patients). Laparoscopy guided selection of primary treatment (primary surgery or neoadjuvant chemotherapy followed by interval surgery). Futile laparotomy, defined as a PCS with residual disease of >1 cm, was the primary outcome.

The researchers found that 63 of 102 patients in the laparoscopy group underwent PCS versus 93 of 99 patients in the primary surgery group. Futile laparotomy occurred in 10 percent of those in the laparoscopy group versus 39 percent in the primary surgery group (relative risk, 0.25). Three percent of patients in the laparoscopy group underwent both primary and interval surgery versus 28 percent of patients in the primary surgery group.

"In women with a plan for PCS, these data suggest that performance of diagnostic laparoscopy first is reasonable and that if cytoreduction to <1 cm of residual disease seems feasible, to proceed with PCS," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »